Skip to main content
. 2014 Jun 20;8(6):ME05–ME08. doi: 10.7860/JCDR/2014/8778.4489

[Table/Fig-5]:

Recommendation by various societies’ guidelines on combination of therapy [19,20,21]

American Thoracic Society (ATS) British Thoracic Society (BTS) Infectious Disease Society of America (IDSA) Canadian Infectious Disease Society (CIDS)
Outpatients with Comorbidities and Previous Antibiotic Therapy
Cephalosporin or β-lactam/β-lactamases inhibitor plus macrolide or Doxycycline or respiratory quinolone Preferred: Amoxicillin plus macrolide or amoxicillin-clavulanic acid or cephalosporin (I,II or III generation) plus macrolide Alternative: respiratory quinolone or respiratory quinolone plus benzylpenicillin Cephalosporin or β-lactam/β-lactamases inhibitor plus macrolide or a respiratory quinolone Cephalosporin (I,II or III generation) plus macrolide
Cap That Requires Hospitalization
No risk for P. aeruginosa infection: Cephalosporin or β-lactam/β-lactamase inhibitor plus macrolide or a respiratory quinolone Risk for P. aeruginosa infection: Antipseudomonal β-lactam plus antipseudomonal quinolone or Antipseudomonal β-lactam plus aminoglycoside and macrolide or respiratory quinolone Cephalosporin or β-lactam/β-lactamase inhibitor plus macrolide or a respiratory quinolone No risk for P. aeruginosa infection: First choice: respiratory quinolone plus III generation cephalosporin or β-lactam/ β-lactamase inhibitor Second choice: Macrolide plus III generation cephalosporin or β-lactam/β-lactamase inhibitor Risk for P. aeruginosa infection: Antipseudomonal quinolone plus Antipseudomonal β-lactam/ Antipseudomonal β-lactam plus aminoglycoside and macrolide Antipseudomonal: β-lactam plus a quinolone and macrolide